SR 16832

CAS No. 2088135-12-8

SR 16832( SR-16832 | SR16832 )

Catalog No. M27795 CAS No. 2088135-12-8

SR 16832 is a dual-site PPARγ inhibitor. It also inhibits the binding of endogenous ligands and transcriptional activity of PPARγ, more effectively than the orthosteric covalent antagonist GW 9662 and T 0070907.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 36 In Stock
10MG 56 In Stock
25MG 113 In Stock
50MG 183 In Stock
100MG 295 In Stock
200MG 427 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    SR 16832
  • Note
    Research use only, not for human use.
  • Brief Description
    SR 16832 is a dual-site PPARγ inhibitor. It also inhibits the binding of endogenous ligands and transcriptional activity of PPARγ, more effectively than the orthosteric covalent antagonist GW 9662 and T 0070907.
  • Description
    SR 16832 is a dual-site PPARγ inhibitor. It also inhibits the binding of endogenous ligands and transcriptional activity of PPARγ, more effectively than the orthosteric covalent antagonist GW 9662 and T 0070907.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    SR-16832 | SR16832
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    PPAR
  • Recptor
    P2X7
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2088135-12-8
  • Formula Weight
    357.75
  • Molecular Formula
    C17H12ClN3O4
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 250 mg/mL (698.81 mM)
  • SMILES
    COc1ccc2nccc(NC(=O)c3cc(ccc3Cl)[N+]([O-])=O)c2c1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Stock TC, et al. Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate. J Rheumatol. 2012 Apr;39(4):720-7.
molnova catalog
related products
  • MK-0533

    MK-0533 is a novel PPARγ partial agonist for the prevention of vascular endothelial dysfunction (VED) and VED-related cardiovascular disease.

  • Methyl oleanonate

    3-Oxoolean-12-en-28-oic acid methyl ester is a triterpenoid PPARγ agonist isolated from Pistacia with anticancer properties.

  • Hydroxyfasudil Hydro...

    Hydroxyfasudil hydrochloride is a ROCK1/2 inhibitor (IC50s: 0.73/0.72 μM).